Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAD+ injection for hospitalized heart failure
ChiCTR2300074326Phase 3Completed
- Sponsor
- Beijing Hospital
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nicotinamide adenine dinucleotide in heart failure (HF) (2 arms), sponsored by Beijing Hospital. Primary endpoint: NT-proBNP at 12 weeks. Started Mar 2021; status: completed.
02
Drugs
nicotinamide adenine dinucleotide
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2300074326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300074326.